Posted by T A P Joe Battipaglia's Market Commentary Genta, Inc. # (GNTA - $6.63 @ 4:00 PM EST, 3/15/01) Genta is a leading antisense drug discovery company, focused on oncology, whose late-stage clinical product, Genasense, has already established substantial proof of efficacy and safety across a wide variety of tumor types. We estimate the market potential for Genasense exceeds $4 billion in the indications currently under development. Genasense is currently in four Phase III trials, with a fifth expected to start in the second quarter of 2001. We expect Genasense will be launched in the third quarter of 2002 for treating malignant melanoma, and will likely experience significant off-label usage beyond our projections due to the abundance of early efficacy studies treating a broad range of tumors in the scientific literature. In 2001, we expect Genta will expand the clinical development of Genasense, initiating late-stage clinical trials in additional oncology indications. Additionally, we expect the company to form two sizable marketing collaborations for Genasense, launch Ganite for treating cancer-related hypercalcemia, and file a new drug application (NDA) for Genasense with the US Food and Drug Administration (FDA) by year-end. Our loss per share estimate for 2001 is $0.19, followed by earnings per share (EPS) for 2002-2006 of $0.16, $0.29, $1.00, $1.97, and $2.57, respectively. Our intermediate- and long-term target prices are $16 and $19, respectively. Ratings System The following chart details how the new system operates: Investment Rating Intermediate Term (Up to 6 months) Long Term (6-18 months)
Link: Join T A P Free!!
on 3/16/2001, 9:07 am
This coverage just hit the newswire and can be found on Gruntals webpage located at
http://www.gruntal.com/research/daily.html
It appears that Gruntal has changed its format with a new rating system and has 3 ratings of which Outperform is the highest rating ( see chart below )
Gruntal Research Selected Trusts
List of Research Industries and Analysts
Investment Calendar
(Refresh your browser for the most recent stock summary)
1-1(Outperform-Outperform)
Intermediate Target Price: $16
Long Term Target Price: $19
Suitability: Aggressive Risk
Initiating Coverage of a Leading Antisense Drug Discovery Company
We initiated coverage of Genta, Inc. (GNTA) on March 15, at $6.63 with a 1-1 rating on the common shares.
Darren Mac
To more clearly define our analysts opinions, we have revised the ratings system by which our Research Department evaluates stocks. This system is designed to assist you in addressing the intermediate and long-term potential of the security.
1 Outperformer Common stock is expected to provide a total return that is five or more percentage points greater than that of the S&P 500 Index. Common stock is expected to provide a total return that is at least 10 percentage points greater than that of the S&P 500 Index.
2 Market Performer Common stock is expected to provide a total return that is within four percentage points +/- that of the S&P 500 Index. Common stock is expected to provide a total return that is within 9 percentage points +/- that of the S&P 500 Index.
3 Underperformer Common stock is expected to provide a total return that is five or more percentage points less than that of the S&P 500 Index. Common stock is expected to provide a total return that is 10 or more percentage points less than that of the S&P 500 Index.
Message Thread:
« Back to thread